Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

Cheung Anthony; Opzoomer James; Ilieva Kristina M.; Gazinska Patrycja; Hoffmann Ricarda M.; Mirza Hasan; Marlow Rebecca; Francesch-Domenech Erika; Fittall Matthew; Rodriguez Diana Dominguez; Clifford Angela; Badder Luned; Patel Nirmesh; Mele Silvia; Pellizzari Giulia; Bax Heather J.; Crescioli Silvia; Petranyi Gyula; Larcombe-Young Daniel; Josephs Debra H.; Canevari Silvana; Figini Mariangela; Pinder Sarah; Nestle Frank O.; Gillett Cheryl; Spicer James F.; Grigoriadis Anita; Tutt Andrew N. J.; Karagiannis Sophia N.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

【24h】

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

机译：抗叶酸受体α-定向抗体疗法限制了三阴性乳腺癌的生长

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose: Highly aggressive triple-negative breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease. Folate receptor alpha (FR alpha) is a central mediator of cell growth regulation that could serve as an important target for cancer therapy.

机译：目的：高度侵略性的三阴性乳腺癌（TNBCS）缺乏验证的治疗靶标，具有高风险的转移性疾病。叶酸受体α（FRα）是细胞生长调节的中央介体，可作为癌症治疗的重要靶标。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2018年第20期|共14页
作者
Cheung Anthony; Opzoomer James; Ilieva Kristina M.; Gazinska Patrycja; Hoffmann Ricarda M.; Mirza Hasan; Marlow Rebecca; Francesch-Domenech Erika; Fittall Matthew; Rodriguez Diana Dominguez; Clifford Angela; Badder Luned; Patel Nirmesh; Mele Silvia; Pellizzari Giulia; Bax Heather J.; Crescioli Silvia; Petranyi Gyula; Larcombe-Young Daniel; Josephs Debra H.; Canevari Silvana; Figini Mariangela; Pinder Sarah; Nestle Frank O.; Gillett Cheryl; Spicer James F.; Grigoriadis Anita; Tutt Andrew N. J.; Karagiannis Sophia N.;
展开▼
作者单位

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Sch Basic &

Med Biosci St Johns Inst Dermatol Tower Wing 9th Floor London SE1;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Sch Basic &

Med Biosci St Johns Inst Dermatol Tower Wing 9th Floor London SE1;

Kings Coll London Sch Basic &

Med Biosci St Johns Inst Dermatol Tower Wing 9th Floor London SE1;

Kings Coll London Sch Basic &

Med Biosci St Johns Inst Dermatol Tower Wing 9th Floor London SE1;

Kings Coll London Sch Basic &

Med Biosci St Johns Inst Dermatol Tower Wing 9th Floor London SE1;

Kings Coll London Sch Basic &

Med Biosci St Johns Inst Dermatol Tower Wing 9th Floor London SE1;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Sch Basic &

Med Biosci St Johns Inst Dermatol Tower Wing 9th Floor London SE1;

Fdn IRCCS Ist Nazl Tumori Milano Dept Appl Res &

Technol Dev Milan Italy;

Fdn IRCCS Ist Nazl Tumori Milano Dept Appl Res &

Technol Dev Milan Italy;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci London England;

Kings Coll London Sch Basic &

Med Biosci St Johns Inst Dermatol Tower Wing 9th Floor London SE1;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci London England;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci London England;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

Kings Coll London Guys Canc Ctr Sch Canc &

Pharmaceut Sci Breast Canc Now Res Unit London;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer [J] . Cheung Anthony, Opzoomer James, Ilieva Kristina M., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第20期

机译：抗叶酸受体α-定向抗体疗法限制了三阴性乳腺癌的生长
2. Triple-Negative Breast Cancers: Associations Between Imaging and Pathological Findings for Triple-Negative Tumors Compared With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancers [J] . Martine Boisserie-Lacroix, Ga??tan MacGrogan, Marc Debled, The oncologist . 2013,第7期

机译：三阴性乳腺癌：与激素受体阳性/人表皮生长因子受体-2-阴性乳腺癌相比，三阴性肿瘤的影像学和病理结果之间的关联
3. CLINICOPATHOLOGICAL AND ULTRASONIC FEATURES OF TRIPLE-NEGATIVE BREAST CANCERS: A COMPARISON WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2-NEGATIVE BREAST CANCERS [J] . Wang Dongmo, Zhu Kai, Tian Jiawei, Ultrasound in Medicine and Biology . 2018,第5期

机译：三阴性乳腺癌的临床病理和超声特征：与激素受体阳性/人表皮生长因子受体-2阴性乳腺癌的比较
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Epidermal growth factor receptor overexpression as a target for imaging and radiotherapy of breast cancer. [D] . Reilly, Raymond Matthew. 1999

机译：表皮生长因子受体过表达作为乳腺癌成像和放射治疗的目标。
6. Anti-Folate Receptor alpha–directed Antibody Therapies Restrict the Growth of Triple Negative Breast Cancer [O] . Anthony Cheung, James Opzoomer, Kristina M Ilieva, -1

机译：抗叶酸受体α抗体治疗限制了三阴性乳腺癌的生长。
7. Comparison of the Mutation Profiles of Triple-Negative Breast Cancers and Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers at the T2N0-1M0 Stage [O] . Seungju Lee, Hyun Yul Kim, Youn Joo Jung, 2020

机译：T2N0-1M0阶段三阴性乳腺癌和激素受体阳性/人表皮生长因子受体2阴性乳腺癌的突变谱比较

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅